These studies highlight the potential of a combination of anti-TGF-β and ICI immunotherapy for patients with EGFR mutations, which might provide new treatments for EGFR-mutated NSCLC patients in the future. This evidence concerns the gene EGFR and non-small cell lung carcinoma.